Damien Le Dû, Dhiba Marigot-Outtandy, Dominique Mathez, Caroline Dupont, Mamadou Saliou Sow, Françoise Borsa-Lebas, Elisabeth Rouveix and Pierre de Truchis
HIV-1 persistent low-level-viremia under 500 copies RNA/ml (PLV) is associated with an increased risk of virological progression and resistance. We performed a study on 18 HIV-1 treated patients who received ARV treatment intensification with maraviroc (MVC) because of PLV during the 6 last months or more. During the 12 months following intensification, CD4 T-cells increased by an average of 104/mm3. Percentage of patients with a plasmatic viral load under 50 copies/ml increased regularly since intensification to reach 71% after 12 months of follow-up. MVC intensification could improve virological and immunological responses in case of PLV.
ఈ కథనాన్ని భాగస్వామ్యం చేయండి
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 